Mitral Valve Prolapse in Pregnancy: Observation and Management
Pregnant women with mitral valve prolapse (MVP) have an excellent prognosis and can be managed conservatively unless severe mitral regurgitation is present. 1
Risk Stratification
The key determinant of pregnancy risk in MVP is the severity of associated mitral regurgitation, not the prolapse itself:
- MVP without significant regurgitation: Excellent prognosis, pregnancy well tolerated 1
- MVP with severe regurgitation: Higher risk of complications, particularly if poorly tolerated before pregnancy 1
What to Observe During Pregnancy
Clinical Monitoring
Monitor for these specific red flags throughout pregnancy:
- Symptoms: New or worsening dyspnea, palpitations, chest pain, syncope
- Functional status: Deterioration to NYHA class III-IV heart failure symptoms
- Arrhythmias: Particularly ventricular arrhythmias (sinus tachycardia 110-140/min at rest is common and usually benign) 2
- Signs of acute severe regurgitation: Sudden clinical deterioration (rare but serious)
Echocardiographic Surveillance
Baseline echocardiography should be performed before pregnancy or early in pregnancy to assess:
- Severity of mitral regurgitation
- Left ventricular dimensions and systolic function (LVEF)
- Pulmonary artery pressures 1
Follow-up echocardiography is indicated if:
- New or worsening symptoms develop
- Baseline severe regurgitation present
- LV dysfunction identified 3
Critical Pitfall: Arrhythmic MVP
Recent evidence identifies a subset of "arrhythmic MVP" associated with life-threatening ventricular arrhythmias, particularly in young women 4. The perinatal period (pregnancy through 6 months postpartum) carries 2.66 times higher risk of malignant ventricular arrhythmias compared to non-pregnant periods 4. Watch for:
- Complex ventricular ectopy
- Non-sustained or sustained ventricular tachycardia
- History of syncope or palpitations
Management Strategy
Medical Management
For symptomatic patients (palpitations, arrhythmias):
- Beta-blockers are first-line therapy 1
- Metoprolol is preferred over atenolol (lower risk of fetal growth retardation) 5
- Calcium channel blockers (dihydropyridines) are alternative if beta-blockers contraindicated 2
For heart failure symptoms (rare unless severe regurgitation):
- Diuretics for pulmonary congestion 1
- Nitrates or dihydropyridine calcium-channel blockers for afterload reduction 1
- ACE inhibitors and ARBs are absolutely contraindicated 1, 3, 5
Delivery Planning
Vaginal delivery is safe and preferred in the vast majority of MVP patients, even those with transient heart failure during pregnancy 1. Hemodynamic monitoring is needed only in the severest cases with refractory symptoms 1.
Antibiotic Prophylaxis
The evidence does not support routine antibiotic prophylaxis for uncomplicated vaginal delivery in MVP patients. Prophylaxis should be reserved for those with:
- Significant mitral regurgitation
- Complicated delivery (instrumentation, infection risk) 6
- History of previous endocarditis
Surgical Intervention
Surgery during pregnancy should be avoided except in life-threatening situations with refractory NYHA class IV heart failure unresponsive to medical therapy 1. This is extremely rare in isolated MVP. Surgery under cardiopulmonary bypass carries 15-30% fetal mortality 7.
Preconception Counseling
For women with severe mitral regurgitation and symptoms or LV dysfunction (LVEF <40%), consider mitral valve repair before pregnancy after detailed discussion of risks and benefits 3, 8. Repair is strongly preferred over replacement to avoid anticoagulation issues.
Postpartum Considerations
Maintain vigilance for 6 months postpartum, as this period carries elevated arrhythmic risk in high-risk MVP patients 4. Continue beta-blocker therapy if initiated during pregnancy for arrhythmias.
Key Takeaway
The overwhelming majority of pregnant women with MVP require only reassurance and symptom-based management. Focus surveillance on detecting the minority who develop severe regurgitation, significant arrhythmias, or heart failure—these are the patients requiring intensified monitoring and potential intervention.